Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.
Here are the top 5 ovarian cancer articles of 2025; stay up-to-date with all the ovarian cancer content from The American ...
The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...
Cirtuvivint is a selective pan-CLK, pan-DYRK inhibitor that modulates alternative RNA splicing, including transcripts involved in oncogenic pathways. Preclinical studies have shown that CLK/DYRK ...
The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone (APP) for adults with deleterious or suspected deleterious BRCA2-mutated ...
Modern Engineering Marvels on MSN
Hidden DNA weak spot near gene start mutates rapidly
These sequences are extremely prone to mutations and rank among the most functionally important regions in the entire human ...
Through a recent notice, the Undergraduate Medical Education Board (UGMEB) of the National Medical Commission (NMC) has ...
ICMR funds new clinical trial to test effective dosing strategy of high-cost cancer drug PARP inhibitor: Our Bureau, Mumbai Monday, December 15, 2025, 17:10 Hrs [IST] Funded by th ...
A research group at the Italian Institute of Technology (Istituto Italiano di Tecnologia - IIT) has identified a candidate molecule that could improve current therapies against pancreatic cancer. The ...
A research group at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has identified a candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback